EMA Proposes Drug Approvals
September 21, 2026
The Committee for Human Medicinal Products of the European Medicines Agency recommends 12 medicines for approval, including treatments for cancer, hemophilia, and hidradenitis suppurativa. Each medicine is intended for specific patient groups and has received a positive evaluation that suggests approval. For instance, Gevalka is a targeted therapy for lung cancer, while Lifyorli is proposed for platinum-resistant ovarian cancer. Povofortay is the first treatment for hidradenitis suppurativa and Frehemgo is for preventing bleeding episodes in patients with hemophilia A. These recommendations do not guarantee immediate approval, as the final decision lies with the European Commission.